



Together we're stronger
Tangata tū pakari tonu

8th January 2024

To: consult@pharmac.govt.nz

Response from BCAC to Proposal to Fund Ribociclib for Breast Cancer

Kia ora Pharmac,

BCAC supports the proposal to include ribociclib on the Pharmaceutical Schedule for unresectable locally advanced or metastatic hormone-receptor positive (HR-positive), human epidermal growth receptor-2 negative (HER2-negative) breast cancer. We would like to see an amendment to the access criteria to enable those who have had to cease treatment with palbociclib due to adverse effects, to have therapy with ribociclib and vice versa. These treatments do not have identical tolerability profiles (Morrison, Loibl et al. 2023), therefore ribociclib should be able to be prescribed in this instance, as should palbociclib where ribociclib is not well tolerated.

We suggest deletion of Special Authority Criterion 6:

Patient has not received prior funded treatment with a CDK4/6 inhibitor.

Reference:

Morrison, L., S. Loibl and N. C. Turner (2023). "The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment." Nat Rev Clin Oncol.

Ngā mihi,

Libby Burgess MNZM

BCAC Chair

libbyb@breastcancer.org.nz

+64 21 990 244



